GLP-1 RAs Improve Glycemic, Weight Outcomes in Pediatric Obesity, Diabetes
GLP-1 RA use was associated with improved cardiometabolic outcomes among pediatric patients with type 2 diabetes and obesity.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with improved glycemic control, weight, and cardiometabolic outcomes without affecting rates of depression, suicidal ideation, or behaviors among children and adolescents with obesity, prediabetes, or type 2 diabetes (T2D), according to study results published in JAMA Pediatrics.
Researchers conducted a systematic review and meta-analysis of 3 databases through February 28, 2025, to identify randomized controlled trials (RCTs) of FDA-approved GLP-1 RAs among individuals younger than 18 years of age.
- Eligible trials compared GLP-1 RAs with placebo, with or without lifestyle modification, and reported both efficacy and safety outcomes.
Author summary: GLP-1 RAs improve outcomes in pediatric obesity and diabetes.
More News
- Dead soldiers’ teeth reveal diseases that doomed Napoleon’s army
- #EyeOnMelissa: Fifty-two shelters open in Portland - Jamaica Observer
- Time for Action: Investing in Health Canada to Accelerate Access to…
- MMJ BioPharma Cultivation: EXPOSÉ: DEA's Marijuana Licensing Scheme Exposed - MMJ BioPharma's Case Reveals DEA Contradiction Blocking FDA Approved Cannabis Medicine
- The 25+ Best Faux Hawk Hairstyles For Men
- #EyeOnMelissa: Councillor raises safety concerns over flood-prone gully near Salt Marsh shelter - Jamaica Observer
- Why Impact Investing Might Collapse and How to Stop It (SSIR)